Euglycemic diabetic ketoacidosis in the setting of acute intracerebral hemorrhage

Author:

Lee Maximus Kyung Hyun1,Ball Perry A.2

Affiliation:

1. Department of Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, United States

2. Department of Surgery, Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, Lebanon, United States

Abstract

Background: Diabetic ketoacidosis (DKA) is a life-threatening condition among diabetic patients characterized by metabolic anion gap (AG) acidosis of arterial pH <7.30, glucose >250 mg/dL, and positive ketones. The triggers for DKA can be infection, surgery, and, in reported cases, intraparenchymal hemorrhage (IPH). In rare cases of DKA, despite being in active ketoacidosis, glucose levels may be within normal or accepted range. Such a condition is called euglycemic DKA. It has been recently recognized in association with the use of sodium glucose co-transporter-2 (SGLT-2) inhibitors in the treatment of type 2 diabetes. Case Description: An 83-year-old male taking an SGLT-2 inhibitor (empagliflozin) for type 2 diabetes presented with an IPH. His laboratory studies revealed an elevated AG acidosis, an elevated beta hydroxybutyrate, and serum glucose levels within the acceptable range. Urine studies revealed elevated ketones and glucose. The diagnosis of euglycemic DKA was made, and the patient was treated with insulin and glucose infusions. Conclusion: Like hyperglycemic ketoacidosis, euglycemic DKA requires prompt recognition and immediate aggressive medical therapy, but the diagnosis can be challenging, and the treatment using insulin in the setting of a normal glucose can be counterintuitive. Euglycemic DKA can often be missed in the setting of blood glucose not being elevated. Prompt recognition and treatment are critical for successful management.

Publisher

Scientific Scholar

Reference18 articles.

1. Euglycemic diabetic ketoacidosis;Barski;Eur J Intern Med,2019

2. Euglycemic ketoacidosis;Bonora;Curr Diab Rep,2020

3. SGLT-2 inhibitors: A new mechanism for glycemic control;Chao;Clin Diabetes,2014

4. SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA adverse event reporting system;Fadini;Diabetologia,2017

5. Diabetic ketoacidosis-associated stroke in children and youth;Foster;Stroke Res Treat,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3